Market news
TypeAll
SortNewest
Assets
MNMD
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durab
Aug 13Yahoo Finance
MNMD
5 Best Psychedelic Stocks for 2026 and How to Invest | The Motley Fool
An in-depth look at the leading psychedelic stocks in the U.S. stock market this year. Here's what you need to know.
This is the newest page. Registered accounts read further back.